专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008070570A3 POSITIVE SELECTION OF SERUM PROTEINS FOR PROTEOMIC ANALYSIS 审中-公开
标题翻译：血清蛋白质对蛋白质分析的正向选择
公开(公告)号：WO2008070570A3
公开(公告)日：2008-11-27
申请号：PCT/US2007086153
申请日：2007-11-30
申请人： CEDARS SINAI MEDICAL CENTER , APPLIED MINDS INC , AGUS DAVID B , HILLIS WILLIAM DANIEL
发明人： AGUS DAVID B , HILLIS WILLIAM DANIEL
IPC分类号： C12Q1/00 , B01L3/00 , B01L99/00 , C12M1/34 , C12M3/00 , C12Q1/68 , G01N1/00 , G01N1/18 , G01N15/06 , G01N33/53 , G01N33/543 , G01N33/566
CPC分类号： G01N33/6803
摘要： This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any species may have on the results of a mass spectra.
摘要翻译：本发明涉及基于来自生物样品的肽/蛋白质序列对感兴趣的物种进行正选择的方法和试剂盒。感兴趣的物种可以是蛋白质和/或感兴趣的肽，其可以通过质谱仪放置以获得血液肽/蛋白质签名。血液肽/蛋白质标签可用于蛋白质组学分析。该技术包括但不限于使用包含核酸分子的收集器从样品中提取具有较低浓度的高丰度物种的组合物。这限制了任何物种对质谱结果的影响程度。

2. 发明申请

WO2006130787A3 METHOD FOR SIMULTANEOUS CALIBRATION OF MASS SPECTRA AND IDENTIFICATION OF PEPTIDES IN PROTEOMIC ANALYSIS 审中-公开
标题翻译：方法同时校准质谱和鉴定肽在分析中的应用
公开(公告)号：WO2006130787A3
公开(公告)日：2007-06-28
申请号：PCT/US2006021321
申请日：2006-05-31
申请人： CEDARS SINAI MEDICAL CENTER , GROTHE ROBERT A JR , AGUS DAVID B
发明人： GROTHE ROBERT A JR , AGUS DAVID B
IPC分类号： B01D59/44
CPC分类号： H01J49/0009
摘要： The invention relates to a mass spectrometry calibration system that may be performed in real-time using the information contained within a sample without the addition of specific calibrants. When applied to a sample, such as a proteomic sample, the calibration system may identify the exact masses of peptides in the sample. The system involves the use of mathematical algorithms that iteratively estimate the error in the measurement and update the calibration parameters accordingly; thereby resulting in peptide mass identification.
摘要翻译：本发明涉及可以使用包含在样品中的信息实时地执行的质谱校准系统，而不添加特定的校准。当应用于诸如蛋白质组样品的样品时，校准系统可以鉴定样品中肽的确切质量。该系统涉及使用迭代估计测量中的误差并相应地更新校准参数的数学算法; 从而导致肽质量鉴定。

3. 发明申请

WO2006130787A2 METHOD FOR SIMULTANEOUS CALIBRATION OF MASS SPECTRA AND IDENTIFICATION OF PEPTIDES IN PROTEOMIC ANALYSIS 审中-公开
标题翻译：方法同时校准质谱和鉴定肽在保护性分析
公开(公告)号：WO2006130787A2
公开(公告)日：2006-12-07
申请号：PCT/US2006/021321
申请日：2006-05-31
申请人： CEDARS-SINAI MEDICAL CENTER , GROTHE, Robert, A., Jr. , AGUS, David, B.
发明人： GROTHE, Robert, A., Jr. , AGUS, David, B.
CPC分类号： H01J49/0009
摘要： The invention relates to a mass spectrometry calibration system that may be performed in real-time using the information contained within a sample without the addition of specific calibrants. When applied to a sample, such as a proteomic sample, the calibration system may identify the exact masses of peptides in the sample. The system involves the use of mathematical algorithms that iteratively estimate the error in the measurement and update the calibration parameters accordingly; thereby resulting in peptide mass identification.
摘要翻译：本发明涉及可以使用包含在样品中的信息实时地执行的质谱校准系统，而不添加特定的校准。当应用于诸如蛋白质组样品的样品时，校准系统可以鉴定样品中肽的确切质量。该系统涉及使用迭代地估计测量中的误差并相应更新校准参数的数学算法; 从而导致肽质量鉴定。

4. 发明申请

WO2004071572A3 GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS 审中-公开
标题翻译：基因表达标志物对EGFR抑制剂药物的反应
公开(公告)号：WO2004071572A3
公开(公告)日：2005-01-13
申请号：PCT/US2004003596
申请日：2004-02-05
申请人： GENOMIC HEALTH INC , CEDARS SINAI MEDICAL CENTER , AGUS DAVID , SHAK STEVE , CRONIN MAUREEN T , BAKER JOFFRE B
发明人： AGUS DAVID , SHAK STEVE , CRONIN MAUREEN T , BAKER JOFFRE B
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular charaterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译：本发明涉及与癌症相关的预后标志物。特别地，本发明涉及基于在石蜡包埋的癌症组织的固定样品中的基因表达的分子特征的预测方法，其允许医师预测患者是否可能对EGFR抑制剂治疗反应良好。

5. 发明申请

WO2004071572A2 GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS 审中-公开
标题翻译：基因表达标志物对EGFR抑制剂药物的反应
公开(公告)号：WO2004071572A2
公开(公告)日：2004-08-26
申请号：PCT/US2004/003596
申请日：2004-02-05
申请人： GENOMIC HEALTH, INC. , CEDARS-SINAI MEDICAL CENTER , AGUS, David , SHAK, Steve , CRONIN, Maureen, T. , BAKER, Joffre, B.
发明人： AGUS, David , SHAK, Steve , CRONIN, Maureen, T. , BAKER, Joffre, B.
IPC分类号： A61N
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular charaterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译：本发明涉及与癌症相关的预后标志物。特别地，本发明涉及基于石蜡包埋的癌组织固定样品中基因表达的分子特征的预测方法，其允许医师预测患者是否可能对EGFR抑制剂治疗反应良好。

6. 发明申请

WO2006093901A3 BI-DIRECTIONAL SYSTEM FOR MASS SPECTROMETRY 审中-公开
标题翻译：用于质谱分析的双向系统
公开(公告)号：WO2006093901A3
公开(公告)日：2008-02-07
申请号：PCT/US2006006924
申请日：2006-02-28
申请人： CEDARS SINAI MEDICAL CENTER , AGUS DAVID B
发明人： AGUS DAVID B
IPC分类号： H01J49/00 , B01D59/44
CPC分类号： H01J49/38
摘要： The present invention relates to a system and method for mass spectrometry (100) that allows for bi-directional introduction of collections of charged particles into the magnetic field of a mass spectrometer. More particularly, the present invention includes a system for mass spectrometry (100)(e.g., an FTMS mass spectrometer) with a cylindrical magnet (101) configured to receive and measure the cyclotron frequencies (104) of charged particles that are introduced (102, 103) into the cylindrical magnet (101) from eith of the two axial ends thereof. Methods of the invention relate to performing mass spectrometry analysis on collections of charged particles that are introduced (102, 103), serially, simultaneously or both, into a cylindrical magnet (101) from opposing axial ends thereof. The present invention exhibits significantly increased magnet throughput relative to currently available devices, by allowing flow in the opposite direction to a second detector, e.g., during ion processing time of a first detector.
摘要翻译：本发明涉及用于质谱（100）的系统和方法，其允许将带电粒子的集合双向引入质谱仪的磁场。更具体地，本发明包括用于质量分析系统（100）（例如，FTMS质谱仪），其中圆柱形磁体（101）被配置为接收和测量引入的带电粒子的回旋加速器（104）（102， 103）从其两个轴向端部的第一位置到圆柱形磁体（101）中。本发明的方法涉及对从其相对的轴向端引入（102,103），串联，同时或两者的带电粒子的集合进行圆柱形磁体（101）的质谱分析。本发明通过允许例如在第一检测器的离子处理时间期间以与第二检测器相反的方向流动，相对于当前可用的装置显示出显着增加的磁体产量。

7. 发明申请

WO2005069891A3 SYSTEM AND METHOD FOR EXPRESSION PROTEOMICS BASED ON ISOTOPE RATIO MODIFICATION 审中-公开
标题翻译：基于同位素比例修正的表达式的系统和方法
公开(公告)号：WO2005069891A3
公开(公告)日：2006-01-26
申请号：PCT/US2005001393
申请日：2005-01-13
申请人： CEDARS SINAI MEDICAL CENTER , WHITELEGGE JULIAN P , AGUS DAVID B , KATZ JONATHAN
发明人： WHITELEGGE JULIAN P , AGUS DAVID B , KATZ JONATHAN
IPC分类号： G01N33/68 , A61K51/00 , A61B5/055 , C07C331/16
CPC分类号： G01N33/6848
摘要： The present invention relates to modification of isotope ratios in peptides and polypeptides as an alternative to full isotopic exchange for coding in proteomics. Subtle modification of isotope ratio does not compromise protein identification experiments and can thus provide elemental composition data for accurate isotope ratio decoding. Application of subtle modification of isotope ratio proteomics (SMIRP) offers a convenient approach to in vivo isotope coding.
摘要翻译：本发明涉及肽和多肽中同位素比率的修饰，作为用于编码蛋白质组学的完全同位素交换的替代物。同位素比率的微妙修改不会影响蛋白质鉴定实验，因此可以提供准确的同位素比率解码的元素组成数据。同位素比蛋白质组学（SMIRP）的微妙修改的应用为体内同位素编码提供了一种方便的方法。

8. 发明申请

WO2005099756A3 ErbB ANTAGONISTS FOR PAIN THERAPY 审中-公开
公开(公告)号：WO2005099756A3
公开(公告)日：2005-10-27
申请号：PCT/US2005/011781
申请日：2005-04-07
申请人： AGUS, David, B.
发明人： AGUS, David, B.
IPC分类号： A61K39/395
摘要： The present application describes the use of ErbB antagonists, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.

9. 发明申请

WO2005020923A3 COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER AND OTHER PHYSIOLOGIC CONDITIONS BASED ON MODULATION OF THE PPAR-GAMMA PATHWAY AND HER-KINASE AXIS 审中-公开
标题翻译：基于调节PPAR-γ途径和HER-激酶轴治疗癌症和其他生理状况的组合物和方法
公开(公告)号：WO2005020923A3
公开(公告)日：2005-10-20
申请号：PCT/US2004028071
申请日：2004-08-27
申请人： CEDARS SINAI MEDICAL CENTER , AGUS DAVID B , JAIN ANJALI , HEDVAT MICHAEL
发明人： AGUS DAVID B , JAIN ANJALI , HEDVAT MICHAEL
IPC分类号： A61K20060101 , A61K31/19 , A61K31/407 , A61K31/47 , A61K39/395 , A61K45/06
CPC分类号： A61K45/06 , A61K31/19 , A61K31/192 , A61K31/405 , A61K31/407 , A61K31/47 , A61K31/60 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： Described herein are methods of using a NSAID and a HER-kinase axis inhibitor in the treatment of various conditions including cancer, and especially prostate, breast, lung, ovarian, brain and colon cancers, through regulation of PPARgamma activity. In various embodiments, the NSAID and HER-kinase axis inhibitor may be included in a composition that is useful for the treatment of conditions in a mammal. Also described is a kit including a NSAID and a HER-kinase axis inhibitor along with instructions for their use in treating and preventing disease conditions, such as cancer.
摘要翻译：本文描述了通过调节PPARγ活性来使用NSAID和HER激酶轴抑制剂在治疗各种病症（包括癌症，特别是前列腺癌，乳腺癌，肺癌，卵巢癌，脑癌和结肠癌）中的方法。在各种实施方案中，NSAID和HER-激酶轴抑制剂可包含在可用于治疗哺乳动物中的病症的组合物中。还描述了包含NSAID和HER-激酶轴抑制剂的试剂盒以及它们用于治疗和预防疾病状况（例如癌症）的说明书。

10. 发明申请

WO1998014170A1 IDIOTYPIC VACCINE IN LIPID BASED CARRIER FOR B CELL DISORDERS 审中-公开
标题翻译：用于B细胞疾病的基于脂蛋白的携带者的异型疫苗
公开(公告)号：WO1998014170A1
公开(公告)日：1998-04-09
申请号：PCT/US1997017513
申请日：1997-09-30
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE LIPOSOME COMPANY, INC. , AGUS, David, B. , JANOFF, Andrew, S. , ZELENETZ, Andrew, D. , AHMAD, Imran , MAYHEW, Eric
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE LIPOSOME COMPANY, INC.
IPC分类号： A61K09/127
CPC分类号： A61K39/0011 , A61K9/1271 , A61K9/1272
摘要： A patient-specific vaccine for non-Hodgkin's lymphoma and other B Cell disorders is made from a lipid-based carrier; and a tumor idiotype derived from B cells from the patient bound to the surface of the lip-based carrier. The idiotype may be absorbed directly to the surface of the lipid-based carrier or bound via an idiotype-binding moiety which is bound to the surface of the lipid-based carrier. When an idiotype binding moiety is used, this moiety is preferably protein G or protein A or a combination thereof. The idiotype need not be prepared from a hybridoma and the use of anti-idiotype murine-derived antibodies is not necessary. Instead, the idiotype can be captured directly from a tumor lysate or other patient-derived material. This makes it possible to prepare a composition in the accordance with the invention and to use it to start the development of an immune response within a period of hours or days, rather than a period of months. The lipid-based carrier is preferably a liposome and may be composed of such lipids as to be an effective adjuvant for the tumor vaccine. The immunotherapeutic composition of the invention can also include additional adjuvants or immunotherapeutic agents incorporated within the liposome. For example, the lipid-based carrier may contain granulocyte-macrophage colony stimulating factor (gmCSF) or cytokines such as interleukin-12 (IL-12) which enhance vaccine-induced immune response.
摘要翻译：用于非霍奇金淋巴瘤和其他B细胞疾病的患者特异性疫苗由基于脂质的载体制成; 和衍生自结合到基于唇缘的载体表面的患者的B细胞的肿瘤独特型。独特型可以直接吸收到基于脂质的载体的表面，或者通过与脂质载体的表面结合的独特型结合部分结合。当使用独特型结合部分时，该部分优选蛋白G或蛋白A或其组合。独特型不需要从杂交瘤制备，并且不需要使用抗独特型鼠源抗体。相反，独特型可以直接从肿瘤裂解物或其他患者来源的材料中捕获。这使得可以根据本发明制备组合物，并且可以在数小时或数天而不是几个月的时间内使用它来开始免疫应答的发展。脂质载体优选为脂质体，并且可以由这样的脂质组成，作为肿瘤疫苗的有效佐剂。本发明的免疫治疗组合物还可以包括掺入脂质体内的另外的佐剂或免疫治疗剂。例如，基于脂质的载体可以含有粒细胞 - 巨噬细胞集落刺激因子（gmCSF）或细胞因子，例如增强疫苗诱导的免疫应答的白细胞介素-12（IL-12）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式